London, Feb 16, 2026, 12:00 GMT — Regular session underway.
• Smith & Nephew slips roughly 0.2% in London by mid-session, trailing a stronger FTSE 100
• Eyes now on the company’s full-year numbers due March 2, plus any update on 2026 guidance
• UK equities inch up, with investors watching for inflation and retail sales figures this week
Shares of Smith & Nephew (SN.L) slipped 0.15% to 1,323 pence by midday in London trading on Monday, moving within a range of 1,311.5 to 1,326.3 pence.
Shares barely budged as the medtech group eyes its next big update—full-year 2025 results drop March 2, marking a key moment for guidance and cash flow clarity. Management will host a webcast at 0700 GMT, then field analyst questions at 0830 GMT.
Timing is key here: London investors are staring down a packed week—data drops, earnings, the works—and interest rate bets are on the move again. By 0925 GMT, the FTSE 100 had tacked on 0.41% to reach 10,488.79. Traders had their eyes fixed on UK inflation and retail sales, with the market leaning toward a quarter-point Bank of England cut next month.
Liquidity is running light across the globe, with U.S. stock and bond markets closed for President’s Day and multiple Asian trading desks offline for the Lunar New Year. That follows Friday’s AI-fueled turbulence in risk assets.
Headlines from the company have been sparse. Smith & Nephew last posted a regulatory update on Investegate with a Feb. 5 results notice, following share-capital changes filed Feb. 2.
Volume was thin. By 11:43 a.m. in London, only around 139,000 shares had traded hands, a far cry from the 2.14 million seen on Friday, according to delayed figures from London South East.
Memories of last December’s reset linger for investors, after Smith & Nephew rolled out new medium-term targets and signaled bigger growth aims following its three-year turnaround. Back then, RBC Capital Markets analyst Jack Reynolds-Clark said he’d “remain nervous until the company can demonstrate reliably that it can generate this growth.” Reuters
The group’s been reworking its portfolio. Back in January, it struck a deal to acquire Integrity Orthopaedics, a U.S. firm, for as much as $450 million. The transaction draws on existing cash facilities and includes earn-outs spread across five years.
Orthopaedics and sports medicine drive most of Smith & Nephew’s revenue—fields dominated by heavyweight U.S. competition, including Stryker, Zimmer Biomet, and Johnson & Johnson’s DePuy arm. The rivalry plays out in squeezed pricing and the pace at which fresh offerings catch on.
On March 2, attention turns to possible tweaks in the 2026 outlook. Investors are zeroing in on “underlying growth”—the company’s term for results stripped of one-offs and currency shifts—as well as free cash flow, the money left once operating costs and capital investments are covered.
Still, there’s a familiar hazard here for medtech: guidance that reads solid enough but can unravel fast if procedure volumes sag, product mix shifts, or costs creep higher. Integration expenses from acquisitions don’t always stay contained, either. And for this sector, tariff-driven manufacturing risk keeps surfacing in conversations.
All eyes now shift to Smith & Nephew’s full-year numbers, due March 2. That report draws the line for where shares go next, deciding if Monday’s drift was simple background static or an early sign of nerves as the results approach.
